Dermatology
2014-10-14T20:51:37+00:00
- About Us
- APR Products
- Prescription Healthcare Products
- Consumer Healthcare Products
- Therapeutical Areas
- Pipeline
- Our Services
- Media
- Contact
Discover who we are and our partners global network, as well as learn more about our people.
Learn more about our products and how they provide innovative solutions for patiens' unmet needs.
Discover our capabilities in project design services.
Find information such as website news, press releases and event presentations.
Get in touch with us to set up a meeting or propose your cooperation.
The dermatological therapeutic market, valued at $21 billion in 2012, is undergoing significant growth due mainly to new drug launches in the psoriasis market.
However, there is still significant unmet medical needs in many areas of dermatology and there is an overall lack of innovation in research and development.
The Dermatological therapeutics market is expected to grow steadily by increase in psoriasis market and other dermatological conditions where several biocellular processes are involved.
Acne is an inflammatory skin disease that affects nearly all adolescents and adults at some stage in their life. Clinical presentation ranges from mild to severe inflammatory cystic acne of the face, chest, and back. Worldwide around 85% of people aged between 15-24 years are affected.
Acne is not a life-threatening condition but can have immense psychological and social effects as well as representing a huge economic burden for healthcare services. According to market research reports by the end of 2018 pharmacological therapy sales for acne are forecasted to reach over $2.8 billion, across the six major pharmaceutical markets (US, France, Germany, Italy, Spain, UK). In order to tackle the increasing problem of acne there is an urgent need for effective prevention and treatment in high-risk groups.
Although in recent years many new products have become available to manage this debilitating condition, the market (currently valued at $2+ billion) is still expected to grow due to the unpredictable and chronic nature of the disease and the large unmet medical needs.
The uptake of biologics, the emergence of therapies that act on different disease targets, and the continued need for topical therapies make this market attractive for new effective and well tolerated therapies.
Atopic dermatitis therapeutic sales in major global markets are forecasted to reach to $5.6 billion by 2022.
Patients with severe dermatitis are currently undertreated as physicians have limited pharmacological options when treatment has failed or patients are intolerant to cyclosporine.
